Open Label Extension to Bridging Study CTBM100C2303
NCT00982930
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Pseudomonas Aeruginosa
Cystic Fibrosis
Interventions
DRUG:
Tobramycin inhalation powder
Sponsor
Novartis Pharmaceuticals